G20 G23.1 G23.2
Conditions
Interventions
Group 1: Patients with clinical diagnosis of neurodegenerative parkinsonian disorder: clinical examination (UPDRS, Hoehn & Yahr), olfactory testing (sniffin sticks test), two brain MRI (at 1.5T and 3.
Sponsors
Medizinische Universität Innsbruck,
Department für Neurologie
Eligibility
Sex/Gender
All
Age
30 Years to 85 Years
Inclusion criteria
Inclusion criteria: patients: 1. clinical diagnosis of PD, MSA or PSP obtained by a neurologist according to published clinical diagnostic criteria; 2. the patient has the ability to communicate well with the investigator and comply with the requirements of the study; 3. written informed consent is obtained; healthy controls: 1. the subject has the ability to communicate well with the investigator and comply with the requirements of the study; 2. written informed consent is obtained;
Exclusion criteria
Exclusion criteria: patients: 1. History of other neurological or psychiatric disorders or conditions; 2. the subject has a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, 4th Edition (DSM-IV); 3. the subject is pregnant; 4. the subject is unsuitable for an MRI study (e.g. Pacemakers); healthy controls: 1. History of neurological or psychiatric disorders or conditions; 2. the subject has a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, 4th Edition (DSM-IV); 3. the subject is pregnant; 4. the subject is unsuitable for an MRI study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the diagnostic value of structural MR findings using routine MRI sequences (T2, T1) at 3.0T versus 1.5T to detect atrophy or signal changes in basal ganglia and infratentorial structures for differential diagnosis of neurodegenerative parkinsonism. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To identify structural changes (atrophy, signal changes) in regional brain structures that distinguish APD from PD and healthy controls and that distinguish between the different APDs; 2. To identify DWI/DTI changes in regional brain structures that distinguish PD from healthy controls; 3. To identify DWI/DTI changes in regional brain structures that distinguish APD from PD and healthy controls and that distinguish between the different APDs; 4. To identify grey or white matter changes in regional brain structures using VBM that distinguish APD from patients with PD and healthy controls as well as between the different APDs. | — |
Countries
Austria
Contacts
Public ContactChristoph Müller
Medizinische Univesität Innsbruck Department für Neurologie Neurologische Studienzentrale
Outcome results
None listed